Neuroendokrin daganatok: vizsgálatok itt: Spanyolország
16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Where
- Barcelona, Madrid, Oviedo
- Életkor
- 12 év and over
- People
- 355 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00 - 3. fázisTaking peopleDAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
- Where
- Badalona, Barcelona, Madrid, Málaga, Pamplona, Santander, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 390 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07544654 · EU 2025-523869-22-00 - 2/3. fázisTaking peopleZanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Where
- Barcelona, Madrid, Murcia, Oviedo, Santander, Santiago de Compostela, Seville, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 440 worldwide
- Run by
- Exelixis
See details and how to joinNCT06943755 · EU 2025-521043-20-00 - No phaseTaking peopleMulticenter Study for External Validation of the TB-NET Score
- Where
- Madrid, Santander
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
See details and how to joinNCT07903532 - 1/2. fázisNot yet taking people in SpanyolországDAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- L'Hospitalet de Llobregat, Madrid, Valencia
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07707895 · EU 2026-525634-27-00 - 3. fázisTaking peopleA clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
- Where
- Barcelona, Madrid
- Életkor
- 18 év and over
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 · EU 2025-524160-38-00 - 1. fázisTaking peoplePhase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Where
- Barcelona, Madrid
- Életkor
- 18 év to 100 év
- People
- 116 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00 - 3. fázisTaking peopleRandomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
- Where
- Barcelona, Burgos, Granada, L'Hospitalet de Llobregat, Madrid, Oviedo, Seville, Valencia
- Életkor
- 18 év and over
- People
- 166 worldwide
- Run by
- Grupo Espanol de Tumores Neuroendocrinos
See details and how to joinNCT06878664 · EU 2024-517921-14-00 - 3. fázisTaking peopleStudy to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Oviedo, Salamanca
- Életkor
- 12 év to 100 év
- People
- 240 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06784752 · EU 2024-518325-15-00 - 3. fázisTaking peopleStudy Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
- Where
- Barcelona, Madrid, Majadahonda, Málaga, Valencia
- Életkor
- 18 év and over
- People
- 156 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-520050-38-00 · EU 2024-520050-38-00 - 2. fázisTaking peopleDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Barcelona, Madrid, Málaga, Valencia
- Életkor
- 18 év and over
- People
- 204 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00 - 1/2. fázisTaking peopleA Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- Where
- Madrid, Pozuelo de Alarcón, Sevilla
- Életkor
- 18 év and over
- People
- 262 worldwide
- Run by
- IDEAYA Biosciences
See details and how to joinNCT07174583 · EU 2025-523438-24-00 - 1/2. fázisTaking peopleStudy in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
- Where
- Boadilla del Monte
- Életkor
- 3 év and over
- People
- 25
- Run by
- Fundación de investigación HM
See details and how to joinNCT06607692 · EU 2024-512613-40-00 - 3. fázisTaking peopleEfficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Oviedo, Santiago de Compostela, Seville, Valencia
- Életkor
- 18 év and over
- People
- 170 worldwide
- Run by
- Grupo Espanol de Tumores Neuroendocrinos
See details and how to joinNCT05918302 · EU 2022-502154-13-00 - No phaseTaking peopleProphylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.
- Where
- Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid
- Életkor
- 18 év and over
- People
- 100
- Run by
- Hospital Universitari de Bellvitge
See details and how to joinNCT04735198 - No phaseTaking peopleSpanish Series of Patients Treated With the Radionuclide Lutetium177
- Where
- Barcelona, Burgos, Ciudad Real, El Palmar, Getafe, Granada, L'Hospitalet de Llobregat, Madrid, Majadahonda, Oviedo, Palma de Mallorca, Pamplona, Santiago de Compostela, Valencia
- Életkor
- 18 év to 100 év
- People
- 5000
- Run by
- Sociedad Española de Medicina Nuclear e Imagen Molecular
See details and how to joinNCT04949282